Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray

BMC Urology

Volumn 13, Issue , 2013, Pages

  Jacobs, Daniel I ^a   Mao, Yingying ^a,b   Fu, Alan ^a   Kelly, William Kevin ^c   Zhu, Yong ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Differential methylation; DLK1; Imprinting; PLAGL1; Prostate cancer; SLC22A18; TP73; WT1

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENOME IMPRINTING; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROSTATE CANCER; QUANTITATIVE STUDY; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE;

BASE SEQUENCE; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS;

EID: 84880894998     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-13-37     Document Type: Article

References (47)

1. DNA methylation and human disease. Robertson KD, Nat Rev Genet 2005 6 8 597 610 16136652
2. Genomic landscape of human allele-specific DNA methylation. Fang F, Hodges E, Molaro A, Dean M, Hannon GJ, Smith AD, P Natl Acad Sci 2012 109 19 7332 7337 10.1073/pnas.1201310109
3. Chromatin mechanisms in genomic imprinting. Kacem S, Feil R, Mamm Genome 2009 20 9 544 556 19760321
4. DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Feinberg AP, Cui H, Ohlsson R, Semin Cancer Biol 2002 12 5 389 398 10.1016/S1044-579X(02)00059-7 12191638
5. Epigenetic drivers and genetic passengers on the road to cancer. Sawan C, Vaissière T, Murr R, Herceg Z, Mutat Res Fundam Mol Mech Mutagen 2008 642 1-2 1 13
6. Loss of Imprinting of Insulin-Like Growth Factor-II (IGF2) Gene in Distinguishing Specific Biologic Subtypes of Wilms Tumor. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber DA, Uejima H, Feinberg AP, J Natl Cancer Inst 2001 93 22 1698 1703 10.1093/jnci/93.22.1698 11717330
7. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB, Clin Cancer Res 1995 1 12 1471 1478 9815946
8. Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. Ribarska T, Ingenwerth M, Goering W, Engers R, Schulz WA, Cancer Genomics Proteomics 2010 7 2 51 60 20335518
9. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF, Prostate 2011 71 15 1621 1630 10.1002/pros.21379 21432864
10. Genome-wide methylation analysis identifies involvement of TNF-α; mediated cancer pathways in prostate cancer. Kim SJ, Kelly WK, Fu A, Haines K, Hoffman A, Zheng T, Zhu Y, Cancer Lett 2011 302 1 47 53 10.1016/j.canlet.2010. 12.010 21237555
11. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Benjamini Y, Hochberg Y, J Roy Stat Soc B Met 1995 57 1 289 300
12. Analysis of Gene Expression Identifies Candidate Markers and Pharmacological Targets in Prostate Cancer. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Hampton GM, Cancer Res 2001 61 16 5974 5978 11507037
13. Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S, Cancer Res 2008 68 3 927 936 10.1158/0008-5472.CAN-07-2608 18245496
14. Gene expression correlates of clinical prostate cancer behavior. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, et al. Cancer Cell 2002 1 2 203 209 10.1016/S1535-6108(02)00030-2 12086878
15. Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al. J Clin Oncol 2004 22 14 2790 2799 10.1200/JCO.2004.05.158 15254046
16. Sex-Determining Region Y Box 4 Is a Transforming Oncogene in Human Prostate Cancer Cells. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, et al. Cancer Res 2006 66 8 4011 4019 10.1158/0008-5472.CAN-05-3055 16618720
17. Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera J-M, Bubley GJ, Li V, Rubin MA, Libermann TA, et al. Clin Cancer Res 2009 15 18 5794 5802 10.1158/1078-0432.CCR- 09-0911 19737960
18. Integrative Genomic Profiling of Human Prostate Cancer. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Cancer Cell 2010 18 1 11 22 10.1016/j.ccr.2010.05.026 20579941
19. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. Cancer Cell 2005 8 5 393 406 10.1016/j.ccr.2005.10.001 16286247
20. Comprehensive Gene Expression Analysis of Prostate Cancer Reveals Distinct Transcriptional Programs Associated with Metastatic Disease. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL, Cancer Res 2002 62 15 4499 4506 12154061
21. Integrative molecular concept modeling of prostate cancer progression. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al. Nat Genet 2007 39 1 41 51 10.1038/ng1935 17173048
22. Transcriptional Silencing of Zinc Finger Protein 185 Identified by Expression Profiling Is Associated with Prostate Cancer Progression. Vanaja DK, Cheville JC, Iturria SJ, Young CYF, Cancer Res 2003 63 14 3877 3882 12873976
23. Frequency and Timing of Loss of Imprinting at 11p13 and 11p15 in Wilms' Tumor Development. Brown KW, Power F, Moore B, Charles AK, Malik KTA, Mol Cancer Res 2008 6 7 1114 1123 10.1158/1541-7786.MCR-08-0002 18644976
24. Progenitor gene DLK1 might be an independent prognostic factor of liver cancer. Z-h J, R-j Y, Dong B, Xing B-c, Expert Opin Biol Ther 2008 8 4 371 377 10.1517/14712598.8.4.371 18352842
25. DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma. Xu X, Liu R-F, Zhang X, Huang L-Y, Chen F, Fei Q-L, Han Z-G, Mol Cancer Ther 2012 11 3 629 638 10.1158/1535-7163.MCT-11-0531 22238367
26. Tumor suppressor gene ZAC/PLAGL1: altered expression and loss of the nonimprinted allele in pheochromocytomas. Jarmalaite S, Laurinaviciene A, Tverkuviene J, Kalinauskaite N, Petroska D, Böhling T, Husgafvel-Pursiainen K, Cancer genet 2011 204 7 398 404 10.1016/j.cancergen.2011.07.002 21872827
27. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. Chu S-H, Feng D-F, Ma Y-B, Zhang H, Zhu Z-A, Li Z-Q, Jiang P-C, J Transl Med 2011 9 1 156 10.1186/1479-5876-9-156 21936894
28. Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery. He H, Xu C, Zhao Z, Qin X, Xu H, Zhang H, Cancer Epidemiol 2011 35 3 279 285 10.1016/j.canep.2010.09.006 21144813
29. Wilms Tumor and the WT1 Gene. Lee SB, Haber DA, Exp Cell Res 2001 264 1 74 99 10.1006/excr.2000.5131 11237525
30. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Silberstein GB, Van Horn K, Strickland P, Roberts CT, Daniel CW, Proc Natl Acad Sci 1997 94 15 8132 8137 10.1073/pnas.94.15.8132 9223327
31. Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Cawkwell L, Lewis FA, Quirke P, Br J Cancer 1994 70 5 813 818 10.1038/bjc.1994.404 7947085
32. Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Oji Y, Miyoshi Y, Koga S, Nakano Y, Ando A, Nakatsuka S-i, Ikeba A, Takahashi E, Sakaguchi N, Yokota A, et al. Cancer Science 2003 94 7 606 611 10.1111/j.1349-7006.2003.tb01490.x 12841869
33. Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome. Sigal A, Rotter V, Cancer Res 2000 60 24 6788 6793 11156366
34. p53 Mutations in human cancers. Hollstein M, Sidransky D, Vogelstein B, Harris CC, Science 1991 253 5015 49 53 10.1126/science.1905840 1905840
35. Gene expression: DNA methylation- how important in gene control? Bird AP, Nature 1984 307 5951 503 504 10.1038/307503a0 6320010
36. DNA methylation: past, present and future directions. Robertson KD, Jones PA, Carcinogenesis 2000 21 3 461 467 10.1093/carcin/21.3.461 10688866
37. DNA methylation and chromatin modification. Ng H-H, Adrian B, Curr Opin Genet Dev 1999 9 2 158 163 10.1016/S0959-437X(99)80024-0 10322130
38. The Role of DNA Methylation in Mammalian Epigenetics. Jones PA, Takai D, Science 2001 293 5532 1068 1070 10.1126/science.1063852 11498573
39. DNA methylation in health and disease. Robertson KD, Wolffe AP, Nat Rev Genet 2000 1 1 11 19 11262868
40. dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats. Baladrón V, Ruiz-Hidalgo MJ, Nueda ML, Díaz-Guerra MJM, García-Ramírez JJ, Bonvini E, Gubina E, Laborda J, Exp Cell Res 2005 303 2 343 359 10.1016/j.yexcr.2004.10.001 15652348
41. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Hafeez BB, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V, Mukhtar H, Clin Cancer Res 2009 15 2 452 459 10.1158/1078-0432.CCR-08-1631 19147749
42. Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence. Murillo H, Schmidt LJ, Karter M, Hafner KA, Kondo Y, Ballman KV, Vasmatzis G, Jenkins RB, Tindall DJ, Gene Chromosome Canc 2006 45 7 702 716 10.1002/gcc.20333
43. Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105. Yamada HY, Gorbsky GJ, Oncogene 2005 25 9 1330 1339
44. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene. Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M, Int J Oncol 2004 24 3 461 471 14767530
45. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Yu J, Baron V, Mercola D, Mustelin T, Adamson E, Cell Death Differ 2006 14 3 436 446 16990849
46. Aging and Cancer-Related Loss of Insulin-like Growth Factor 2 Imprinting in the Mouse and Human Prostate. Fu VX, Dobosy JR, Desotelle JA, Almassi N, Ewald JA, Srinivasan R, Berres M, Svaren J, Weindruch R, Jarrard DF, Cancer Res 2008 68 16 6797 6802 10.1158/0008-5472.CAN-08-1714 18701505
47. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP, Nat Med 1998 4 11 1276 1280 10.1038/3260 9809551